PrEP
Anti-HIV drug PrEP has 30% lower concentration levels in pregnant African adolescents and young women
March 10, 2020Manufacturing and Production AIDS, HIV, PrEP, PrEP HIV, insulin
Pregnant African adolescents and young women who took the HIV drug PrEP were found to have 30% lower levels of …
HIV infections fall by 73% in bi and gay British men
January 16, 2020Business Services AIDS, AIDS Epidemic, HIV, NHS, NHS England, PrEP, nhs scotland
Public Health England has released figures that show that HIV rates in bi and gay men have fallen by 73% …
Gilead challenges Government over patents on preventative HIV drug Truvada
August 22, 2019Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents
Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …
Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says
August 8, 2019Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma
Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …
MSD trials long lasting PrEP implant for preventing HIV
July 23, 2019Research and Development AIDS, HIV, MSD, PrEP, pharma
MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …
Top Ten most popular articles on Pharmafile.com this week!
July 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brenntag, Elizabeth Warren, HIV, Novartis, PrEP, cannabis, crispr, pharma
The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to …
Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada
May 17, 2019Medical Communications Gilead, HIV, PrEP, Truvada, patent, pharma
On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a …
Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump
May 10, 2019Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy
Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …
Gilead accused of ripping off US taxpayers
March 28, 2019Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents
Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …
Those at risk of HIV to be offered PrEP drugs in England and Northern Ireland
July 27, 2018Medical Communications AIDS, England, HIV, PrEP, Terrence Higgins Trust
Those at risk of contracting HIV will now be offered PrEP drugs in England and Northern Ireland through a programme …
Anti-HIV drug PrEP proves safety in gay and bisexual adolescents
September 6, 2017Research and Development Gilead, HIV, Pharamceuticals, PrEP, Truvada, health, medicine, pharma
A new study has found that pre-exposure prophylaxis (PrEP) drugs such as Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), which pre-emptively protects …
HIV-preventing drug to be trialed across England
August 7, 2017Medical Communications, Sales and Marketing NHS, NHS England, PrEP, Truvada, biotech, drugs, pharma, pharmaceutical
NHS England has announced that it will finally make the HIV-preventing drug, PrEP, available to those at risk with the …
HIV cases in gay men fall for the first time in England
June 23, 2017Medical Communications HIV, PrEP
For the first time in English history, new diagnoses of HIV have fallen across the country – the drop was …
Gilead gets EU approval for HIV-prevention treatment Truvada
August 23, 2016Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention
Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …
The power of PrEP
August 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug
Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
